Researchmoz added Most up-to-date research on "Actinic Keratosis-Market Insights, Epidemiology and Market Forecast-2023" to its huge collection of research reports.
DelveInsights Actinic Keratosis - Market Insights, Epidemiology and Market Forecast-2023-7MM report provides an overview of the disease and global market size of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
According to DelveInsight, the market size for Actinic Keratosis in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.5% for the forecast period i.e., 2013-2023. Market size covered in our report, is based only upon the topical therapies approved for Actinic Keratosis.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1069399
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Actinic Keratosis market.
Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition of Actinic Keratosis therapies in the 7MM and Insightful review of the key market drivers and barriers.
The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Actinic Keratosis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Table Of Content
Report Introduction 2
Actinic Keratosis Market Overview at a Glance 9
7 MM Market Size of Actinic Keratosis (2013-2023) 9
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2016 10
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2023 10
Overview 11
Signs and symptoms 11
Risk Factors 11
Pathophysiology 13
Diagnosis 15
Histopathology 15
Epidemiology and Patient Population 16
United States 16
Europe 18
Germany 19
France 20
United Kingdom 21
Italy 22
Spain 24
Japan 26
Treatment Algorithm 28
Lesion-Directed Therapies: 29
Field-Directed Therapies 29
Photodynamic therapy 30
Marketed Drugs 32
Aldara: Valeant Pharmaceuticals 32
Drug Description 32
Mechanism of Action 32
Regulatory Milestones 32
Advantages & Disadvantages 33
Safety and Efficacy of Aldara 33
Product Profile 33
Zyclara: Valeant Pharmaceuticals 34
Drug Description 34
Mechanism of Action 34
Regulatory Milestones 34
Advantages & Disadvantages 35
Safety and Efficacy of Zyclara 35
Product Profile 36
Solaraze: Sandoz Pharmaceuticals 37
Drug Description 37
Regulatory Milestones 37
Advantages & Disadvantages 38
Safety and Efficacy of Solaraze 38
Product Profile 38
Efudex: Valeant Pharmaceutical 39
Drug Description 39
Mechanism of Action 39
Regulatory Milestones 39
Advantages & Disadvantages 39
Safety and Efficacy of Efudex 40
Product Profile 40
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1069399
DelveInsights Actinic Keratosis - Market Insights, Epidemiology and Market Forecast-2023-7MM report provides an overview of the disease and global market size of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
According to DelveInsight, the market size for Actinic Keratosis in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.5% for the forecast period i.e., 2013-2023. Market size covered in our report, is based only upon the topical therapies approved for Actinic Keratosis.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1069399
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Actinic Keratosis market.
Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition of Actinic Keratosis therapies in the 7MM and Insightful review of the key market drivers and barriers.
The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Actinic Keratosis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Table Of Content
Report Introduction 2
Actinic Keratosis Market Overview at a Glance 9
7 MM Market Size of Actinic Keratosis (2013-2023) 9
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2016 10
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2023 10
Overview 11
Signs and symptoms 11
Risk Factors 11
Pathophysiology 13
Diagnosis 15
Histopathology 15
Epidemiology and Patient Population 16
United States 16
Europe 18
Germany 19
France 20
United Kingdom 21
Italy 22
Spain 24
Japan 26
Treatment Algorithm 28
Lesion-Directed Therapies: 29
Field-Directed Therapies 29
Photodynamic therapy 30
Marketed Drugs 32
Aldara: Valeant Pharmaceuticals 32
Drug Description 32
Mechanism of Action 32
Regulatory Milestones 32
Advantages & Disadvantages 33
Safety and Efficacy of Aldara 33
Product Profile 33
Zyclara: Valeant Pharmaceuticals 34
Drug Description 34
Mechanism of Action 34
Regulatory Milestones 34
Advantages & Disadvantages 35
Safety and Efficacy of Zyclara 35
Product Profile 36
Solaraze: Sandoz Pharmaceuticals 37
Drug Description 37
Regulatory Milestones 37
Advantages & Disadvantages 38
Safety and Efficacy of Solaraze 38
Product Profile 38
Efudex: Valeant Pharmaceutical 39
Drug Description 39
Mechanism of Action 39
Regulatory Milestones 39
Advantages & Disadvantages 39
Safety and Efficacy of Efudex 40
Product Profile 40
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1069399
No comments:
Post a Comment